"The Evaluation of Stimulant Withdrawal"

Phase 2

Withdrawn

• Conditions: Anxiety; Substance Addiction; Relapse
• Interventions: Drug: Coreg

• Registration Number: NCT00442923
• Lead Sponsor: Aaron J. Janowsky

Brief Summary

The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-03-02
• Study First Submitted QC: 2007-03-02
• Study First Posted: 2007-03-05
• Study Start: 2007-07-01
• Primary Completion: 2010-06-30
• Study Completion: 2011-06-30
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-29
• Last Update Posted: 2019-01-31

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center
• Must meet the clinical definition for methamphetamine dependence
• Self-reported methamphetamine use within 10 days of entering the study
• Must be able to understand and sign the consent form

Read More

Exclusion Criteria

• Dependent on any other drug except nicotine, caffeine, marijuana and alcohol
• Pregnant or nursing mothers
• Psychosis
• Dementia
• Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid)
• History of withdrawal seizures or delirium tremors
• Use of MAO inhibitors within the last two weeks
• Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
TREAT	Coreg	-
CTRL	Coreg	-

Trial Locations

Locations (1)

US Veterans Hospital; 🇺🇸 Portland, Oregon, United States